This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Illumina will work with EU regulator in pursuit of approval for Grail acquisition

( July 22, 2021, 17:24 GMT | Official Statement) -- MLex Summary: Illumina said it would continue to pursue its acquisition of Grail, a cancer-testing company, despite the European Commission opening an in-depth review of the transaction. Illumina said it had offered "far-reaching structural and behavioral remedies," but these have not assuaged the commission's competition concerns. The company is also before the EU courts contesting the commission's decision to assert jurisdiction over the deal, which it says "reversed decades of merger policy."The statement follows:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login